1. “Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma 
Cristina Gasparetto, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, George Keogh, John P. Chute, Keith M. Sullivan, Rachel Neuwirth, Patricia H. Davis, Linda M. Sutton, Russell D. Anderson, Nelson J. Chao, David Rizzieri 
Biology of Blood and Marrow Transplantation 
Volume 16, Issue 1, Pages (January 2010)
DOI: /j.bbmt
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Time to progression, (B) progression-free survival, and (C) overall survival among all patients receiving VMP, according to transplant status.
Biology of Blood and Marrow Transplantation  , 70-77DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions